



(51) International Patent Classification:

A61K 38/46 (2006.01) C12N 9/22 (2006.01)
C12N 5/10 (2006.01) C12N 15/11 (2006.01)
C12N 9/16 (2006.01) C12N 15/13 (2010.01)

(21) International Application Number:

PCT/US2020/025454

(22) International Filing Date:

27 March 2020 (27.03.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/825,007 27 March 2019 (27.03.2019) US

(71) Applicant: **RESEARCH INSTITUTE AT NATION-
WIDE CHILDREN'S HOSPITAL** [US/US]; 700
Children's Drive, W-148, Columbus, OH 43205 (US).

(72) Inventors: **LEE, Dean, Anthony**; 2561 Sitterly Road,
Canal Winchester, OH 43205 (US). **MEYER, Kathrin,
Christine**; 700 Children's Drive, Columbus, OH 43205
(US). **KARAROUDI, Meisam, Nacimi**; 8372 Seattle Av-


enue, Apt 10110, Columbus, OH 43240 (US). **LIKHTE,
Shibi**; 700 Children's Drive, WA 4112, Columbus, OH
43205 (US).

(74) Agent: **LANIER, J., Gibson** et al.; 999 Peachtree St. NE,
Suite 1300, Atlanta, GA 30309 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR)-PRIMARY NK CELLS FOR CANCER IMMUNOTHER-
APY USING A COMBINATION OF CAS9/RNP AND AAV VIRUSES



Electroporation of fCas9/RNP into Day 7 expanded NK cells

FIG. 11

(57) Abstract: Disclosed are methods for genetically engineering cells using Adeno-associated viral (AAV) delivery of a CRISPR/CAS9 system and ribonucleoproteins for integration. In some aspects, disclosed herein are AAV plasmids for performing said methods

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*